

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee, 2017
(including the 20th WHO Model List of Essential Medicines
and the 6th Model List of Essential Medicines for Children)



World Health
Organization

WHO Technical Report Series
1006

The Selection and Use of Essential Medicines

Report of the WHO Expert Committee, 2017
(including the 20th WHO Model List of Essential Medicines
and the 6th WHO Model List of Essential Medicines for Children)

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO model list of essential medicines and the 6th WHO model list of essential medicines for children).

(WHO technical report series ; no. 1006)

ISBN 978-92-4-121015-7

ISSN 0512-3054

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2017 (WHO technical report series ; no. 1006). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of a WHO Expert Committee and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Italy.

Contents

| | |
|---|------|
| Executive summary | vii |
| List of participants | xix |
| Declaration of interests | xxii |
| 1.Introduction | 1 |
| 2.Open session | 2 |
| 3.General items | 4 |
| 3.1: Alignment of the Essential Medicines List and WHO guidelines | 4 |
| 3.2: New format for the Technical Report | 4 |
| 3.3: Increasing the affordability of high-priced medicines | 5 |
| 3.4: EML Working Groups and comprehensive reviews | 5 |
| 3.5: Proposal for a WHO list of essential in vitro diagnostics | 6 |
| 4.Summary of recommendations | 7 |
| Additions to Model Lists | 7 |
| Deletions from Model Lists | 8 |
| Changes to listings | 8 |
| New indications | 8 |
| New dosage form and/or strength | 9 |
| Rejected applications | 9 |
| 5.Applications for the 20th Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children | 12 |
| Section 1: Anaesthetics, preoperative medicines and medical gases | 12 |
| 1.4: Medical gases (new section) | 12 |
| <i>Oxygen</i> | 12 |
| Section 2: Medicines for pain and palliative care | 17 |
| 2.1: Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs) | 17 |
| <i>Paracetamol</i> | 17 |
| 2.2: Opioid analgesics | 19 |
| <i>Fentanyl</i> | 19 |
| <i>Methadone</i> | 24 |
| <i>Tramadol</i> | 31 |
| 2.3: Medicines for other common symptoms in palliative care | 37 |
| <i>Gabapentin</i> | 37 |
| Section 5: Anticonvulsants/antiepileptics | 45 |
| <i>Lamotrigine</i> | 45 |
| Section 6: Anti-infective medicines | 55 |
| 6.1: Anthelmintics | 55 |

| | | |
|----------|--|-----|
| 6.1.1: | Intestinal anthelmintics | 55 |
| | <i>Ivermectin</i> | 55 |
| 6.2: | Antibacterials | 62 |
| | Comprehensive review of antibiotics | 62 |
| | <i>Overview</i> | 62 |
| | <i>Community-acquired pneumonia (CAP)</i> | 69 |
| | <i>Pharyngitis</i> | 76 |
| | <i>Sinusitis</i> | 79 |
| | <i>Otitis media</i> | 82 |
| | <i>Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)</i> | 85 |
| | <i>Sepsis in children</i> | 89 |
| | <i>Urinary tract infections</i> | 92 |
| | <i>Meningitis</i> | 96 |
| | <i>Complicated intra-abdominal infections</i> | 99 |
| | <i>Acute infectious diarrhoea</i> | 112 |
| | <i>Sexually transmitted infections</i> | 118 |
| | <i>Exacerbations of chronic obstructive pulmonary disease</i> | 126 |
| | <i>Bone and joint infections</i> | 130 |
| | <i>Febrile neutropenia</i> | 134 |
| | <i>Severe acute malnutrition</i> | 139 |
| | <i>Proposal from the McMaster Group for a “conserved” antibiotics list – for preservation, niche indications, and last-resort use.</i> | 143 |
| 6.2.2: | Other antibacterials | 146 |
| | <i>Azithromycin</i> | 146 |
| 6.2.4: | Antituberculosis medicines | 150 |
| | <i>Clofazimine</i> | 150 |
| | <i>Delamanid c</i> | 155 |
| | <i>Gatifloxacin</i> | 159 |
| | <i>Isoniazid + pyrazinamide + rifampicin</i> | 164 |
| | <i>Isoniazid + rifampicin</i> | 164 |
| | <i>Ofloxacin</i> | 168 |
| | <i>Streptomycin</i> | 171 |
| 6.3: | Antifungal medicines | 173 |
| | <i>Itraconazole</i> | 173 |
| | <i>Voriconazole</i> | 181 |
| 6.4: | Antiviral medicines | 186 |
| 6.4.2: | Antiretrovirals | 186 |
| | <i>ARV formulations</i> | 186 |
| 6.4.2.1: | Nucleoside/Nucleotide reverse transcriptase inhibitors | 191 |
| | <i>Abacavir</i> | 191 |
| | <i>Zidovudine (ZDV or AZT)</i> | 194 |
| 6.4.2.3: | Protease inhibitors | 197 |
| | <i>Atazanavir + ritonavir</i> | 197 |
| | <i>Lopinavir + ritonavir</i> | 200 |
| 6.4.2.4: | Integrase inhibitors (new subsection) | 204 |
| | <i>Dolutegravir</i> | 204 |
| | <i>Raltegravir</i> | 208 |
| | FIXED-DOSE COMBINATIONS | 212 |

| | |
|--|-----|
| <i>Abacavir + lamivudine</i> | 212 |
| <i>Cobicistat + elvitegravir + emtricitabine + tenofovir alafenamide</i> | 215 |
| <i>Efavirenz + lamivudine + tenofovir disoproxil fumarate</i> | 220 |
| <i>Emtricitabine + tenofovir alafenamide</i> | 223 |
| <i>Emtricitabine + rilpivirine + tenofovir alafenamide</i> | 228 |
| <i>Tenofovir disoproxil fumarate</i> | 234 |
| <i>Emtricitabine + tenofovir disoproxil fumarate</i> | 234 |
| <i>Lamivudine + tenofovir disoproxil fumarate</i> | 234 |
| 6.4.2.5: Medicines for prevention of HIV-related opportunistic infections (new subsection) | 240 |
| <i>Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim</i> | 240 |
| 6.4.3: Other antivirals | 245 |
| <i>Oseltamivir</i> | 245 |
| 6.4.4: Antihepatitis medicines | 254 |
| 6.4.4.1: Medicines for hepatitis B | 254 |
| <i>Tenofovir alafenamide</i> | 254 |
| 6.4.4.2: Medicines for hepatitis C | 259 |
| <i>Elbasvir + grazoprevir</i> | 259 |
| <i>Sofosbuvir + velpatasvir</i> | 265 |
| 6.5: Antiprotozoal medicines | 272 |
| 6.5.3: Antimalarial medicines | 272 |
| 6.5.3.1: For curative treatment | 272 |
| <i>Artesunate + pyronaridine</i> | 272 |
| <i>Artesunate</i> | 277 |
| <i>Dihydroartemisinin + piperaquine</i> | 281 |
| Section 8: Antineoplastics and immunosuppressives | 286 |
| 8.2: Cytotoxic and adjuvant medicines | 286 |
| <i>Erlotinib, gefitinib, afatinib, crizotinib</i> | 286 |
| <i>Nilotinib, dasatinib</i> | 293 |
| <i>Trastuzumab emtansine</i> | 299 |
| <i>Zoledronic acid</i> | 307 |
| 8.3: Hormones and antihormones | 314 |
| <i>Enzalutamide</i> | 314 |
| Section 10: Medicines affecting the blood | 320 |
| 10.1: Antianaemia medicines | 320 |
| <i>Erythropoiesis-stimulating agents</i> | 320 |
| Section 12: Cardiovascular medicines | 339 |
| 12.3: Antihypertensive medicines | 339 |
| <i>Lisinopril + hydrochlorothiazide</i> | 339 |
| <i>Losartan</i> | 345 |
| 12.7: Fixed-dose combinations of cardiovascular medicines (new subsection) | 351 |
| <i>Aspirin + atorvastatin + ramipril</i> | 351 |
| Section 15: Disinfectants and antiseptics | 361 |
| 15.1: Antiseptics | 361 |
| <i>Hypochlorous acid</i> | 361 |

| | |
|--|-----|
| Section 18: Hormones, other endocrine medicines and contraceptives | 366 |
| 18.3: Contraceptives | 366 |
| 18.3.1: Oral hormonal contraceptives | 366 |
| <i>Ulipristal acetate</i> | 366 |
| 18.3.2: Injectable hormonal contraceptives | 371 |
| <i>Medroxyprogesterone acetate</i> | 371 |
| 18.5: Insulins and other medicines used for diabetes | 375 |
| <i>Long-acting insulin analogues –</i> | 375 |
| <i>Second-line treatments for type 2 diabetes</i> | 382 |
| Section 21: Ophthalmological preparations | 401 |
| 21.1: Anti-infective agents | 401 |
| <i>Natamycin</i> | 401 |
| 21.6: Anti-vascular endothelial growth factor (VEGF) preparations | 405 |
| <i>Bevacizumab</i> | 405 |
| Section 22: Oxytocics and antioxytocics | 408 |
| 22.1: Oxytocics | 408 |
| <i>Misoprostol</i> | 408 |
| Section 25: Medicines acting on the respiratory tract | 413 |
| 25.1: Antiasthmatics and medicines for chronic obstructive pulmonary disease | 413 |
| <i>Budesonide + formoterol</i> | 413 |
| Section 26: Solutions correcting water, electrolyte and acid–base disturbances | 418 |
| 26.3: Miscellaneous | 418 |
| <i>Ready to use therapeutic food (RUTF)</i> | 418 |
| Annex 1 | 424 |
| WHO Model List of Essential Medicines (March 2017) | 424 |
| Annex 2 | 485 |
| WHO Model List of Essential Medicines for Children (March 2017) | 485 |
| Annex 3 | 531 |
| The Anatomical Therapeutic Chemical (ATC) Classification System | 531 |

1006 . 2017

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26593

